Effectiveness of Vazonat in the comprehensive therapy of patients with type 2 diabetes mellitus on the background of cardiovascular disease
Background. In accordance with the postulates of the National Cholesterol Education Program, type 2 diabetes mellitus (DM) is classified as coronary heart disease equivalent of risk. Purpose of this work is to investigate the dynamics of anthropometric indexes, parameters of carbohydrate metabolism, markers of insulin resistance (IR), indexes of hepatic complex, coagulogram, urinary acid, glomerular filtration rate (GFR), and also instrumental indexes in patients with type 2 DM during differentiated hypoglycemic and metabolic therapy by Vazonat preparation for 6 and 9 months. Materials and methods. Under supervision, there were 60 patients with type 2 DM in the state of decompensation, who received Vazonat 10 ml intravenously as metabolic therapy during 10 days from the beginning of the research and 1000 μg/day orally for prolongation of the course during 6 and 9 months. Influence of Vazonat was studied on the background the differentiated hypoglycemic therapy: by oral hypoglycemic preparations (metformin, 30 patients), combination therapy with metformin and NPH insulin (second group, 30 individuals). Study of the dynamics of carbohydrate metabolism indexes and IR markers was conducted in patients at the beginning of the research and during 6 and 9 months. Results. Vazonat strengthens the effect of hypoglycemic therapy, influences the IR indexes and anthropometric parameters, lipidogram values, hepatic complex, urinary acid level, prothrombin index, GFR and positively influences the dynamics of left ventricular ejection fraction. Conclusions. It is expedient to prescribe Vazonat as additional metabolic therapy for the improvement of clinical course and disease prognosis, and also for the improvement of quality of life in patients with type 2 DM and hepato- and nephropathy, coronary heart disease, arterial hypertension, gout, violations of blood lipid spectrum.
Full Text:PDF (Українська)
Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. Br J Diabetes Vasc Dis. 2013;13(4):192-207. doi: 10.1177/1474651413495703.
Regidor E, Franch J, Seguí M, Serrano R, Rodríguez-Artalejo F, Artola S. Traditional risk factors alone could not explain the excess mortality in patients with diabetes: a national cohort study of older Spanish adults. Diabetes Care. 2012 Dec;35(12):2503-9. doi: 10.2337/dc11-1615.
Luijks H, Schermer T, Bor H, et al. Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study. BMC Med. 2012;10:128. doi: 10.1186/1741-7015-10-128.
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012 Jul 7;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2.
Wang J, Imai K, Engelgau MM, Geiss LS, Wen C, Zhang P. Secular trends in diabetes-related preventable hospitalizations in the United States, 1998-2006. Diabetes Care. 2009 Jul;32(7):1213-7. doi: 10.2337/dc08-2211.
Vinagre I, Mata-Cases M, Hermosilla E, et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care. 2012 Apr;35(4):774-9. doi: 10.2337/dc11-1679.
Copyright (c) 2020 K.Yu. Maliar, O.S. Anisimova, O.I. Drishliuk, L.Yu. Bykovska, E.V. Filipova
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020